Submission Number: 00003
Received: 10/7/2011 5:10:01 PM
State: Outside the United States
Agency: Federal Trade Commission
Initiative: Proposed Consent Agreement In the Matter of Teva Pharmaceutical Industries Ltd. and Cephalon, Inc., File No. 111-0166
Attachments: No Attachments
Thank you for providing us the opportunity to take part in public debate.
I am wondering why it is required Teva to sell its rights and assets to Par Pharmaceuticals Inc., a generic drug manufacturer based in New Jersey, and not to another company in or out US (EU for instance).
Which are the crucial criteria?
D. A. Temperis
Attorney at Law